You are here: Industry Insights > Biomarker

News List

The Landscape of Biomarkers: From Traditional Measures to Multi-Omics Powerhouses Shruti Talshi
February 18, 2024
A biomarker is an indicator that can be quantified to show whether a biological process is pathogenic, normal, or responding to an intervention or exposure.
Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD) prnasia
February 07, 2022
Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application...
Innovent and Eli Lilly announce final clinical results and biomarker analysis of phase-Ib study of Sintilimab injection plus Bevacizumab biosimilar injection ExpressPharma
January 24, 2022
The Overall Response Rate (ORR) was 34 per cent (17/50) and ORRs for the low-dose and high-dose groups were 31 per cent and 38 per cent, respectively...
Serum Biomarkers Can Differentiate Psoriatic Arthritis, RA drugs.com
December 21, 2021
A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA), according to a study recently published in Arthritis & Rheumatology.
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune, Successfully Produced Memory-Like NK Cells firstwordpharma
August 26, 2021
INmune Bio, Inc. (NASDAQ: INMB) announced today that the first patient who received INKmune™ as a potential treatment for high-risk myelodysplastic syndrome (MDS) has successfully shown the NK activation and functional differentiation predicted.
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use prnewswire
August 17, 2021
Avidity Biosciences, Inc. today announced its collaboration with the Facioscapulohumeral Muscular Dystrophy (FSHD) Clinical Trial Research Network (FSHD CTRN) to support a natural history study for people living with FSHD called the Motor Outcomes.
Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology prnasia
August 06, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company today ...
UT Southwestern finds crucial new molecular mechanisms and biomarkers in ovarian cancer firstwordpharma
August 02, 2021
UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.
New research identifies single biomarker that can indicate underlying neurodegeneration pharmatimes
June 09, 2021
New research has identified a single biomarker that can be used to accurately identify underlying neurodegeneration among people with cognitive issues.
SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting b3cnewswire
June 07, 2021
SOTIO today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.